Hits and misses in targeting pediatric cancers

Pediatric Blood and Cancer

Volumn 52, Issue 7, 2009, Pages 751-752

  Bernstein, Mark L ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB;

CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL LINE; CHILDHOOD CANCER; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; EDITORIAL; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; INFANT; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES;

EID: 67650481560     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21937     Document Type: Editorial

References (16)

1. Mazur T, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7:507-519.
2. Kitamura Y. Gastrointestinal stromal tumors: Past, present and future. J Gastroenterol 2008;43:499-508.
3. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 2001;20:5054-5058. (Pubitemid 32769795)
4. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620-625. (Pubitemid 351264357)
5. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-L 632. (Pubitemid 351264358)
6. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-5367.
7. Janeway KA, Liegl B, HarlowA, et al. Pediatric KIT-wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 2007;67:9084-9088. (Pubitemid 47535893)
8. Janeway K, Albritton K, van den Abbeele A. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer (in press).
9. Heinrich MC, Maki RC, Corless CL. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352-5359.
10. Joske DJL. Chronic myeloid leukaemia: The evolution of gene-targeted therapy. Med J Aust 2008;189:277-282.
11. Reed SD, Anstrom KJ, Li Y, et al. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. Pharmacoeconomics 2008;26:435-446. (Pubitemid 351572054)
12. Champagne MA, Fu CH, Chang M, et al. Imatinib for treatment of children with newly diagnosed chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group AAML0123 phase II study. Blood 2006;108:A2140.
13. Merchant MS, Woo CW, Mackall CL, et al. Potential use of imatinib in Ewing's sarcoma: Evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-1679. (Pubitemid 35446835)
14. Druker BJ. Taking aim at Ewing's sarcoma: Is KIT a target and will imatinib work? J Natl Cancer Inst 2002;94:1660-1661.
15. Bond M, Bernstein ML, Pappo A, et al.Aphase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 2008; 50:254-258.
16. Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12: 3532-3540. (Pubitemid 43910901)